argenx registers Phase 2 trial of empasiprubart for Guillain-Barré syndrome
A new NCT07821762 registry listing details a placebo-controlled study adding empasiprubart to IVIg in adults with GBS, not yet recruiting.
This week's update centers on a single new trial registration for argenx.
- This Phase 2, randomized, double-blinded, placebo-controlled study will assess the efficacy and safety of empasiprubart as add-on therapy to IVIg in adult participants with Guillain-Barré syndrome.1 The record was first posted on 2026-09-16 and lists the overall status as not yet recruiting, with an estimated start of 2026-12. About 63 participants will be assigned by chance to receive either empasiprubart or placebo by intravenous infusion, with all participants also receiving IVIg.1 The primary endpoint is the proportion of participants with a Guillain-Barré Syndrome Disability Scale (GBS-DS) score ≤2 at week 4, indicating the participant is able to walk 10 meters or more without assistance.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.